Get the Daily Brief
Latest Biotech News
FDA Clears Biocartis’ Idylla System MSI Test to Guide Immunotherapy in Cancer
Biocartis’ Idylla CDx MSI Test received FDA premarket approval to detect microsatellite instability (MSI) in formalin-fixed tissue. It aids in guiding immunotherapy treatments such as Bristol...
Trump’s Drug Tariffs Threaten Small Biotechs Despite Carve-Outs
The Trump administration announced 100% tariffs on branded drug imports starting October 1, 2025. While exemptions exist for generics, European exports, and companies investing in US...
AI-Powered Advances in Biotech Diagnostics and Clinical Research
Artificial intelligence is driving breakthroughs across biotech, from AI-enhanced ultrasound diagnostics to innovative tools for clinical research acceleration. Ultromics reported superior...
Breakthroughs in Cancer Research and Therapeutics
New findings spotlight molecular targets and innovative therapies across cancer types. UCLA researchers identified IGF2BP3 as a dual regulator of leukemia metabolism and RNA methylation, opening...
Pediatric and Neonatal Health Advances
Clinical studies enhance understanding of interventions and challenges in neonatal and pediatric care. The CARE trial showed a combination inhaler reduces childhood asthma exacerbations by nearly...
Innovations in Biotech Infrastructure and Investment
Concept Life Sciences unveiled expanded integrated drug discovery facilities in the UK, combining chemistry, ADMET, and screening biology to accelerate early-stage therapeutic development....
Cutting-Edge Biomedical Engineering and Biobots
Carnegie Mellon researchers engineered 'AggreBots'—microscale living robots made from human lung cells capable of programmable motility—potentially enabling targeted drug delivery inside the body....
Advances in Radiation Oncology Techniques and Cancer Therapy
Leading cancer centers showcased novel radiation oncology technologies to improve treatment precision and outcomes. UCLA Health highlighted targeted radioactive therapy approaches for recurrent...
Crinetics Wins FDA Nod for Oral Acromegaly Drug Palsonify
Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first once-daily oral therapy for adults with acromegaly who have had inadequate response to surgery or are not...
Trump Administration Imposes 100% Tariffs on Drug Imports Starting Oct 1
President Donald Trump announced a 100% import tariff on branded drug imports effective October 1, 2025, escalating trade tensions with the pharmaceutical industry. Carve-outs for generics and...
Breakthrough Dual-Payload ADC Collaboration Aims at Solid Tumors
Lonza’s Synaffix entered a licensing agreement with Qurient Therapeutics to develop a dual-payload antibody-drug conjugate (ADC) leveraging Synaffix’s clinical-stage GlycoConnect®, HydraSpace®,...
AI-Powered Diagnostic Advances: Ultromics and LungPro Models
Ultromics showcased FDA-cleared AI-enhanced ultrasound diagnostics detecting cardiac amyloidosis with improved sensitivity and earlier diagnosis at the 2025 scientific session. Meanwhile, a novel...
ARPA-H Launches Nine-Figure Programs to Scale Personalized Gene Editing
The Advanced Research Projects Agency for Health (ARPA-H) unveiled two new multiyear funding programs totaling nine figures: THRIVE, to accelerate development of custom in vivo precision gene...
Cancer Metabolism and RNA Regulation Linked via IGF2BP3 in Leukemia
UCLA researchers identified IGF2BP3 as a master regulator that rewires leukemia cell metabolism and RNA methylation pathways to promote rapid cancer proliferation. This protein enhances glycolytic...
Innovative Protein Switches Enable Safer Precision Medicines
University of Washington researchers developed engineered protein switches that precisely control therapeutic protein activity duration in the body. Unlike traditional affinity modulation, these...
New RNA-Based Therapy Reverses Osteoarthritis in Preclinical Model
A novel circular RNA (circRNA) therapeutic demonstrated profound efficacy in alleviating osteoarthritis progression in male mice through targeted protein replacement mechanisms. This approach...
Clinical and Technological Advances Highlighted at ASTRO 2025 Meeting
Leading oncology centers presented breakthroughs in radiation therapy including targeted radioactive treatments for recurrent prostate and pancreatic cancers, and long-term data confirming...
Standardized Organoid Modeling Center Launches to Replace Animal Testing
The U.S. NIH awarded $87 million to establish the Standardized Organoid Modeling Center aiming to develop reproducible protocols for organoid research, elevating its role in drug discovery and...
FDA Clears Crinetics’ Oral Treatment for Rare Hormone Disorder Acromegaly
Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first oral once-daily therapy for adults with acromegaly, an endocrine disorder caused by excess growth hormone....
Eli Lilly’s Oral SERD Imlunestrant Approved for Advanced Breast Cancer
The U.S. FDA has approved Eli Lilly's imlunestrant (Inluriyo), an oral selective estrogen receptor degrader (SERD), for adults with estrogen receptor-positive, HER2-negative, ESR1-mutant advanced...